Strides Shasun

Press Release
Friday, November 25, 2016

Strides to acquire PediaCare from Moberg Pharma

Brand acquisition to strengthen Consumer Health Care portfolio

Bangalore, November 25, 2016. Strides Shasun Limited today announced that its wholly owned subsidiary Strides Arcolab International Limited, UK has entered into an agreement with Moberg Pharma, Sweden to acquire the 'PediaCare' brand for a total consideration of US$ 5 million plus inventory value at closing.

PediaCare is an established paediatric cough, cold and allergy brand with annual sales of approximately US$ 6 Million. PediaCare will form an important part of Strides expanding consumer health care portfolio and brings with it expertise in the paediatric segment as well as a strong brand name with global potential.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 13 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

Strides Shasun	PR Consultancy
Badree Komandur, Group CFO +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	**Fortuna PR** K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com